Clinical benefit (R-FC vs FC) in FCGR2A and FCGR3A variant subgroups
| . | n . | R-FC vs FC . | |||
|---|---|---|---|---|---|
| FC . | R-FC . | PFS hazard ratio (95% CI), P, power . | OS hazard ratio (95% CI), P, power . | ORR % (P) . | |
| FCGR2A | |||||
| HH | 56 | 54 | .7 (0.41-1.18), .18, 0.26 | 0.9 (0.39-2.08), .8, 0.04 | 76 vs 46 (.0018) |
| HR or RR | 153 | 156 | 0.68 (0.51-0.93), .015, 0.69 | 0.88 (0.55-1.41), .6, 0.08 | 66 vs 62 (.48) |
| HR | 102 | 116 | 0.63 (0.44-0.9), .012, 0.72 | 0.94 (0.56-1.58), .81, 0.04 | 66 vs 61 (.4) |
| RR | 51 | 40 | 0.82 (0.47-1.42), .48, 0.11 | 0.53 (0.17-1.65), .27, 0.2 | 65 vs 65 (1) |
| FCGR3A | |||||
| VV | 29 | 20 | 0.86 (0.4-1.84), .7, 0.06 | 0.84 (0.28-2.51), .75, 0.05 | 75 vs 59 (.36) |
| FV or FF | 180 | 190 | 0.68 (0.51-0.9), .0066, 0.78 | 0.94 (0.6-1.46), .77, 0.05 | 68 vs 58 (.052) |
| FV | 96 | 106 | 0.55 (0.37-0.8), .002, 0.88 | 0.71 (0.39-1.28), .25, 0.21 | 69 vs 59 (.19) |
| FF | 84 | 84 | 0.85 (0.56-1.29), .44, 0.12 | 1.33 (0.67-2.63), .42, 0 | 67 vs 56 (.2) |
| . | n . | R-FC vs FC . | |||
|---|---|---|---|---|---|
| FC . | R-FC . | PFS hazard ratio (95% CI), P, power . | OS hazard ratio (95% CI), P, power . | ORR % (P) . | |
| FCGR2A | |||||
| HH | 56 | 54 | .7 (0.41-1.18), .18, 0.26 | 0.9 (0.39-2.08), .8, 0.04 | 76 vs 46 (.0018) |
| HR or RR | 153 | 156 | 0.68 (0.51-0.93), .015, 0.69 | 0.88 (0.55-1.41), .6, 0.08 | 66 vs 62 (.48) |
| HR | 102 | 116 | 0.63 (0.44-0.9), .012, 0.72 | 0.94 (0.56-1.58), .81, 0.04 | 66 vs 61 (.4) |
| RR | 51 | 40 | 0.82 (0.47-1.42), .48, 0.11 | 0.53 (0.17-1.65), .27, 0.2 | 65 vs 65 (1) |
| FCGR3A | |||||
| VV | 29 | 20 | 0.86 (0.4-1.84), .7, 0.06 | 0.84 (0.28-2.51), .75, 0.05 | 75 vs 59 (.36) |
| FV or FF | 180 | 190 | 0.68 (0.51-0.9), .0066, 0.78 | 0.94 (0.6-1.46), .77, 0.05 | 68 vs 58 (.052) |
| FV | 96 | 106 | 0.55 (0.37-0.8), .002, 0.88 | 0.71 (0.39-1.28), .25, 0.21 | 69 vs 59 (.19) |
| FF | 84 | 84 | 0.85 (0.56-1.29), .44, 0.12 | 1.33 (0.67-2.63), .42, 0 | 67 vs 56 (.2) |
CI indicates confidence interval.